WallStSmart
NBIX

Neurocrine Biosciences Inc

NASDAQ: NBIX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$131.23
+2.43% today

Updated 2026-04-29

Market cap
$13.20B
P/E ratio
28.10
P/S ratio
4.61x
EPS (TTM)
$4.67
Dividend yield
52W range
$108 – $160
Volume
1.1M

Neurocrine Biosciences Inc (NBIX) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item20062007200820092010201120122013201420152016201720182019202020212022202320242025
Operating cash flow$-99.33M$-59.33M$-74.17M$-53.09M$49.94M$-698000.00$-35.29M$-29.61M$-47.14M$-38.00M$-106.18M$-94.33M$101.40M$147.00M$228.50M$256.50M$339.40M$389.90M$595.40M$782.70M
Capital expenditures$3.11M$624000.00$1.32M$35000.00$315000.00$750000.00$971000.00$545000.00$1.61M$1.93M$4.11M$6.94M$24.80M$14.70M$10.90M$23.40M$16.50M$28.30M$38.20M$34.00M
Depreciation$10.57M$9.40M$7.61M$3.18M$1.44M$694000.00$657000.00$671000.00$827000.00$1.01M$1.45M$2.40M$4.00M$7.40M$8.60M$10.90M$15.60M$21.30M$27.10M$30.10M
Stock-based comp$14.37M$9.98M$7.99M$5.54M$3.13M$2.92M$5.48M$6.82M$10.38M$28.39M$28.46M$42.52M$58.10M$75.30M$100.00M$134.20M$173.10M$194.30M$195.50M$217.90M
Free cash flow$-102.44M$-59.96M$-75.49M$-53.13M$49.63M$-1.45M$-36.27M$-30.15M$-48.75M$-39.93M$-110.29M$-101.27M$76.60M$132.30M$217.60M$233.10M$322.90M$361.60M$557.20M$748.70M
Investing cash flow$120.28M$20.84M$44.42M$12.06M$-54.70M$-3.53M$-34.76M$5.34M$-105.37M$-195.81M$112.95M$-251.25M$-242.90M$-211.10M$4.10M$-130.20M$-177.10M$-467.10M$-126.80M$-264.40M
Financing cash flow$10.09M$57.18M$-1.45M$9.90M$21.48M$286000.00$83.70M$5.30M$138.73M$276.99M$2.39M$516.65M$29.50M$32.40M$-157.80M$27.40M$-234.30M$65.30M$-486.70M$-38.30M
Dividends paid$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Share repurchases
Debt repayment
Net change in cash$-3.94M$13.65M$-18.96M$-13.78M$43.18M$9.07M$171.44M$-112.02M$-31.71M$74.80M$153.70M$-72.00M